Gastric (Stomach) Cancer: Diagnosis, Multimodality Therapy, and Surgical Management

Gastric cancer requires careful integration of tumor biology, precise staging, and coordinated multimodality therapy. Modern treatment combines systemic therapy, surgery, and—in selected cases—radiation therapy to achieve durable disease control.

Care is delivered through a multidisciplinary program integrating surgical oncology, medical oncology, gastroenterology, radiology, pathology, and nutrition specialists. Treatment sequencing is individualized according to tumor stage, location within the stomach, histologic subtype, and patient-specific physiologic considerations.

As a fellowship-trained robotic surgical oncologist serving the San Francisco Bay Area, Dr. Geoffrey W. Krampitz provides surgical management of gastric cancer using evidence-based oncologic principles and advanced minimally invasive techniques when appropriate.

Understanding Gastric Cancer

The stomach is a muscular organ responsible for food storage and early digestion. Gastric cancers arise from the inner lining of the stomach and may occur in the:

  • proximal stomach (near the gastroesophageal junction)

  • body of the stomach

  • distal stomach (near the pylorus)

Tumor location influences both surgical approach and lymph node dissection strategy.

Most gastric cancers are adenocarcinomas, though less common subtypes may occur.

Risk factors may include:

  • Helicobacter pylori infection

  • chronic gastritis

  • smoking

  • dietary factors

  • hereditary cancer syndromes in selected patients

Because early-stage gastric cancer may produce few symptoms, many patients present once tumors begin affecting digestion or causing bleeding.

Symptoms of Gastric Cancer

Symptoms often develop gradually and may include:

  • early satiety or feeling full quickly

  • abdominal discomfort or bloating

  • nausea or indigestion

  • unexplained weight loss

  • anemia from slow gastrointestinal bleeding

More advanced tumors may cause:

  • difficulty eating

  • vomiting

  • obstruction of the stomach outlet

Early detection through endoscopy can identify tumors at a stage where curative treatment is possible.

Staging and Pre-Treatment Evaluation

Accurate staging determines treatment strategy and surgical candidacy.

Evaluation typically includes:

  • CT scan of the chest, abdomen, and pelvis

  • upper endoscopy with biopsy

  • endoscopic ultrasound (EUS) for local tumor staging

  • PET scan in selected cases

Because gastric cancer frequently spreads to the peritoneal cavity, diagnostic laparoscopy is often performed before definitive surgery to detect microscopic peritoneal metastases not visible on imaging.

This step helps ensure appropriate treatment sequencing.

Multimodality Treatment Strategy

Curative treatment for gastric cancer typically requires combined systemic therapy and surgery.

Historically, surgery alone was often performed first for localized disease. Modern treatment strategies now emphasize systemic therapy to treat micrometastatic disease and improve long-term outcomes.

Perioperative chemotherapy—established by trials such as FLOT—has become a standard treatment approach for many patients with resectable gastric and gastroesophageal junction adenocarcinoma.

This strategy involves systemic therapy administered both before and after surgery to:

  • reduce tumor burden

  • treat microscopic metastatic disease

  • improve rates of complete tumor removal

Advances in immunotherapy and molecular profiling are further expanding treatment options. Increasingly, biomarker testing may identify tumors that respond to targeted or immune-based therapies.

Relevant molecular markers may include:

  • HER2 amplification

  • PD-L1 expression

  • microsatellite instability (MSI)

  • CLDN18.2 expression

Integration of these biomarkers may influence systemic therapy selection and clinical trial eligibility.

Treatment sequencing is determined through multidisciplinary evaluation that integrates tumor biology, stage, and patient physiology.

Surgical Management

Surgery remains a cornerstone of curative treatment for localized gastric cancer.

The type of operation depends on tumor location and extent.

Possible procedures include:

Subtotal (Distal) Gastrectomy

Removal of the lower portion of the stomach, typically performed for tumors located in the distal stomach.

Total Gastrectomy

Removal of the entire stomach, typically required for tumors involving the proximal stomach or diffuse disease.

Reconstruction restores digestive continuity by connecting the esophagus to the small intestine.

Lymph Node Dissection

An essential component of gastric cancer surgery is systematic lymph node removal.

Modern oncologic gastrectomy typically includes D2 lymphadenectomy, which involves removal of lymph nodes along the major vascular structures supplying the stomach.

Adequate lymph node harvest is critical for:

  • accurate staging

  • improved oncologic outcomes

  • guiding postoperative treatment decisions

These dissections require careful understanding of upper abdominal vascular anatomy.

Robotic and Minimally Invasive Gastrectomy

Advances in minimally invasive and robotic surgery have refined gastric cancer operations.

Robotic platforms provide:

  • magnified three-dimensional visualization

  • enhanced dexterity during lymph node dissection

  • improved precision within the upper abdomen

In experienced programs, minimally invasive gastrectomy may support:

  • reduced wound complications

  • shorter hospital stays

  • faster recovery

However, operative approach is individualized based on tumor anatomy and oncologic safety. Complete tumor removal with appropriate lymphadenectomy remains the primary objective.

Learn more about surgical philosophy and techniques in the Robotic Surgery section.

Potential Risks After Surgery

Gastrectomy is a major abdominal operation requiring specialized postoperative care.

Potential complications may include:

  • bleeding

  • infection

  • anastomotic leak

  • delayed gastric emptying

  • nutritional challenges following surgery

Careful perioperative management and structured follow-up help minimize these risks.

Recovery and Long-Term Follow-Up

Recovery depends on:

  • response to systemic therapy

  • extent of surgery

  • baseline nutritional status

  • overall physiologic reserve

Postoperative care includes:

  • nutritional counseling

  • surveillance imaging

  • monitoring for recurrence

Patients who undergo total gastrectomy also receive long-term nutritional guidance to maintain vitamin and micronutrient balance.

Multidisciplinary Gastric Cancer Care

Optimal management of gastric cancer requires coordination among multiple specialties.

Care typically involves collaboration among:

  • surgical oncology

  • medical oncology

  • gastroenterology

  • radiology

  • pathology

  • nutrition specialists

Treatment decisions are individualized through multidisciplinary discussion to align tumor biology, staging, and patient goals.

Conclusion: Multimodality Care for Gastric Cancer

Gastric cancer treatment requires careful staging, integration of systemic therapy, and technically precise surgical management.

When delivered within experienced multidisciplinary programs, modern multimodality therapy—including minimally invasive gastrectomy when appropriate—offers the best opportunity for durable disease control and meaningful recovery.

Consultation and Referral

For Patients:
Individuals seeking evaluation for gastric cancer may Request a Consultation to discuss individualized treatment strategies.

For Referring Physicians:
Physicians wishing to refer a patient or discuss complex upper gastrointestinal cancers may visit For Physicians for coordinated referral pathways and case review.